���构特征与受体作用机制 — Deep Dive

By Editorial Desk · published 2025-12-28 · last reviewed 2026-02-03 · Wiki

peptide half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Peptide Background and Receptor Mechanism

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

Semaglutide at a glance

Background and Drug Class

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Related pages on this site

• Proven handbook
• Portable review
• Scheduled comparison
• Practical playbook
• Smart report
• Optimized guide
• Professional toolkit
• Lightweight guide

Background and Molecular Profile

The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

Background from the literature

=== Class IV: Asp-based DSPs === The haloacid dehalogenase (HAD) superfamily is a further PP group that uses Asp as a nucleophile and was recently shown to have dual-specificity. These PPs can target both Ser and Tyr, but are thought to have greater specificity towards Tyr. A subfamily of HADs, the Eyes Absent Family (Eya), are also transcription factors and can therefore regulate their own phosphorylation and that of transcriptional cofactor/s, and contribute to the control of gene transcription. The combination of these two functions in Eya reveals a greater complexity of transcriptional gene control than previously thought . A further member of this class is the RNA polymerase II C-terminal domain phosphatase. While this family remains poorly understood, it is known to play important roles in development and nuclear morphology.

=== Geena Williams-Conner === Geena Williams-Conner is played by Maya Lynne Robinson (Rae'Ven Larrymore Kelly in season 7 and Xosha Roquemore in season 10). The African-American wife of D.J. and mother of Mary; she is, like D.J., a military veteran. The character was introduced in a 1994 Roseanne episode wherein D.J. must kiss her for a school play, but is reluctant to do so because she is black (race). D.J. overcomes his prejudices and kisses her for the play; she is not seen on the original show again. In the Season 10 revival, it is revealed that Geena had married D.J., and while D.J. is home raising their daughter, she is still an active-duty soldier. She was a main character in season one of The Conners, having been discharged from the military after a tour in Afghanistan. In Season 2, she is called into active duty again. In an interview with MEAWW, Robinson explained that the show did not have her character return as a regular, and that she was joining another sitcom as a main character in The Unicorn.

===== Huntington's disease ===== Tominersen (also known as IONIS-HTTRx and RG6042) was tested in a phase 3 trial for Huntington's disease although this trial was discontinued on March 21, 2021, due to lack of efficacy. It is currently licensed to Roche by Ionis Pharmaceuticals.

==== Distribution ==== The brain tissue distribution of muscimol in rats has been studied. Muscimol rapidly enters and unevenly distributes in rat brain, especially in the substantia nigra, colliculi, and hypothalamus. Muscimol crosses the blood–brain barrier and hence is centrally active. This has been said to likely be mediated by active transport via the high-affinity GABA uptake system and other amino acid transporters. Although muscimol crosses the blood–brain barrier, it does so relatively poorly and far less readily than gaboxadol.

Sources: en.wikipedia.org

Further detail

Monoclonal+antibodies at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Antibodypedia, open-access virtual repository publishing data and commentary on any antibodies available to the scientific community. Antibody Purification Handbook Archived 5 December 2008 at the Wayback Machine

Because of this, and also because the high-glycerol method seems to protect the red blood cells better and is associated with less haemolysis than the low-glycerol method, the high-glycerol method is often preferred.

=== Environmental factors === Hyperglycemia is lower in higher income groups since there is access to better education, healthcare, and resources. Low-middle income groups are more likely to develop hyperglycemia, due in part to a limited access to education and a reduced availability of healthy food options. Living in warmer climates can reduce hyperglycemia due to increased physical activity while people are less active in colder climates.

Sources: en.wikipedia.org

Background from the literature

As a result of their rapid growth rates, mussel recolonization of a disturbed seep site could occur relatively rapidly. There is some evidence that mussels also have some requirement of a hard substrate and could increase in numbers if suitable substrate is increased on the seafloor (Fisher, 1995). Two associated species are always found associated with mussel beds—the gastropod Bathynerita naticoidea and a small Alvinocarid shrimp—suggesting these endemic species have excellent dispersal abilities and can tolerate a wide range of conditions (MacDonald, 2002). Unlike mussel beds, chemosynthetic clam beds may persist as a visual surface phenomenon for an extended period without input of new living individuals because of low dissolution rates and low sedimentation rates. Most clam beds investigated by Powell (1995) were inactive. Living individuals were rarely encountered. Powell reported that over a 50-year timespan, local extinctions and recolonization should be gradual and exceedingly rare. Contrasting these inactive beds, the first community discovered in the Central Gulf of Mexico consisted of numerous actively-plowing clams. The images obtained of this community were used to develop length/frequency and live/dead ratios as well as spatial patterns (Rosman et al., 1987a). Extensive bacterial mats of free-living bacteria are also evident at all hydrocarbon seep sites. These bacteria may compete with the major fauna for sulfide and methane energy sources and may also contribute substantially to overall production (MacDonald, 1998b).

For example, neighborhood associations amended housing contracts to contain phrases such as "undesirable" rather than "Black" to avoid the explicit discrimination of housing based on race. These slight revisions in already racist housing contracts allowed neighborhood associations to remain legally immune during the discriminatory protection of middle-class homeownership from the perceived social disorder and housing depreciation of racially integrated neighborhoods. Therefore, throughout the history of restrictive covenants, the preservation of the social and economic stability of middle-class neighborhoods hardened the residential segregation of black Detroiters by placing restrictions on black homeownership. Overall, restrictive covenants reinforced unequal race relations and perpetuated racial divisions that continue to exacerbate the urban inequality of current-day Detroit. Coupled with the ability of de jure discrimination to mandate residential segregation through policy, neighborhood associations curbed civil rights reform that sought to mitigate racism within housing. The middle-class mentality of neighborhood associations would govern the political climate of Detroit as this anti-integration constituency resonated with politicians who would dispel public housing and the threat of racial invasion. The 1949 mayoral election of Detroit pitted George Edwards, a UAW activist and public housing advocate, against Albert Cobo, a corporate executive and real estate investor.

=== Acute calculous cholecystitis === Gallstones blocking the flow of bile account for 90% of cases of cholecystitis (acute calculous cholecystitis). Blockage of bile flow leads to thickening and buildup of bile causing an enlarged, red, and tense gallbladder. The gallbladder is initially sterile but often becomes infected by bacteria, predominantly E. coli, Klebsiella, Streptococcus, and Clostridium species. Inflammation can spread to the outer covering of the gallbladder and surrounding structures such as the diaphragm, causing referred right shoulder pain.

(1) Most often, 5'-DMT group is removed at the end of the oligonucleotide chain assembly. The oligonucleotides are then released from the solid phase and deprotected (base and phosphate) by treatment with aqueous ammonium hydroxide, aqueous methylamine, their mixtures, gaseous ammonia or methylamine or, less commonly, solutions of other primary amines or alkalies at ambient or elevated temperature. This removes all remaining protection groups from 2'-deoxyoligonucleotides, resulting in a reaction mixture containing the desired product. If the oligonucleotide contains any 2'-O-protected ribonucleotide residues, the deprotection protocol includes the second step where the 2'-O-protecting silyl groups are removed by treatment with fluoride ion by various methods. The fully deprotected product is used as is, or the desired oligonucleotide can be purified by a number of methods. Most commonly, the crude product is desalted using ethanol precipitation, size exclusion chromatography, or reverse-phase HPLC. To eliminate unwanted truncation products, the oligonucleotides can be purified via polyacrylamide gel electrophoresis or anion-exchange HPLC followed by desalting. (2) The second approach is only used when the intended method of purification is reverse-phase HPLC. In this case, the 5'-terminal DMT group that serves as a hydrophobic handle for purification is kept on at the end of the synthesis. The oligonucleotide is deprotected under basic conditions as described above and, upon evaporation, is purified by reverse-phase HPLC.

Sources: en.wikipedia.org

Frequently asked questions